News Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
8.08 ^USD	-0.25%		+6.32%	-29.37%

Mar. 28	Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	CI
Feb. 29	Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call	Apr. 25	BU
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	Mar. 28	BU
Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	Mar. 28	CI
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure	Mar. 01	AQ
Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	Feb. 29	MT
Investors Await Slate of Economic Data as US Futures Move Lower in Thursday's Premarket Session	Feb. 29	MT
Top Premarket Decliners	Feb. 29	MT
Transcript : Ironwood Pharmaceuticals, Inc. - Special Call	Feb. 29
Ironwood says bowel disease treatment meets main goal in late-stage trial	Feb. 29	RE
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)	Feb. 29	BU
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science and Practice Conference	Feb. 26	AQ
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference	Feb. 23	BU
Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $21 From $20, Maintains Overweight Rating	Feb. 16	MT
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results, Achieves 2023 Financial Guidance	Feb. 16	AQ
Ironwood Pharmaceuticals Insider Sold Shares Worth $2,699,979, According to a Recent SEC Filing	Feb. 15	MT
Ironwood Pharmaceuticals Insider Sold Shares Worth $588,538, According to a Recent SEC Filing	Feb. 15	MT
Ironwood Pharmaceuticals Insider Sold Shares Worth $722,071, According to a Recent SEC Filing	Feb. 15	MT
Ironwood Pharmaceuticals Q4 Non-GAAP Net Income Drops, Revenue Rises	Feb. 15	MT
Transcript : Ironwood Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Ironwood: Q4 Earnings Snapshot	Feb. 15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Summary

Filters